Disease: Mucormycosis

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate

mycolabadmin

Doctors and researchers use standard definitions to determine if antifungal treatments work in clinical trials. This debate examines whether the standards created in 2008 are still appropriate today. Key concerns include whether stable disease should always count as treatment failure, how to handle deaths from other causes, and whether newer testing methods should be incorporated. The expert panel concluded these definitions need updating to reflect modern treatment options and patient needs.

Read More »

Advancing Patient Advocacy in Mycology: Cultivating Collaboration in Education, Research, and Policy

mycolabadmin

Fungal infections are a serious public health problem, but unlike cancer and AIDS, they lack strong patient advocacy movements to raise awareness and secure funding. This paper argues that patients with fungal diseases have important insights about their care needs that could help improve policies and research if their voices were heard. The authors propose establishing unified advocacy organizations, like the MyCARE Foundation, to bring patients, doctors, and policymakers together to better address this neglected health challenge.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

This study found that COVID-19 patients in northwestern Iran who received high-dose steroid treatment developed serious fungal infections called mucormycosis. The infection was caused primarily by a fungus called Rhizopus arrhizus and affected mainly the sinuses and brain. The steroids used to treat COVID-19 weakened patients’ immune systems and triggered diabetes, both of which made them vulnerable to this dangerous fungal infection.

Read More »

Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics

mycolabadmin

This editorial discusses the growing challenge of fungal infections worldwide, which disproportionately affect people with weakened immune systems. New diagnostic tools using molecular testing can now quickly identify fungal infections, while researchers are developing novel treatments including repurposed drugs and immune-boosting therapies. The article emphasizes that coordinated efforts among doctors, scientists, and public health officials are essential to combat rising antifungal resistance and improve patient outcomes.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »
Scroll to Top